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interpretation of PSA results
Abstract
Background: Prostate-specific antigen (PSA) is used as an 
outcome measure for relapsed disease in prostate cancer. 
Nonetheless, there are considerable concerns about its 
indiscriminate use as a surrogate endpoint for cell growth or 
survival. We hypothesized that treatment with a luteinizing 
hormone releasing hormone (LHRH) analog would decrease 
PSA levels even in the absence of malignant disease.
Methods: We determined testosterone and PSA levels in 
30 healthy volunteers after a single intramuscular injec-
tion of a LHRH depot formulation. Testosterone and PSA 
levels were quantified by radioimmunoassay and electro-
chemi-luminescence immunoassay, respectively.
Results: After an initial flare-up during the first 3  days 
testosterone decreased reaching castration levels in 18 of 
the 30 young men (60%). After the nadir on day 28, testos-
terone levels increased to normal again. Changes in PSA 
paralleled those of testosterone. Castration reduced PSA 
levels by 29% (95% CI 19%–39%) compared to baseline 
(p < 0.0001).
Conclusions: LHRH superagonists decrease PSA levels 
by testosterone deprivation. Conferring these findings 
to tumor patients, decreases in PSA after treatment with 
LHRH analogs might not only reflect disease regression 
but also a direct testosterone mediated effect on PSA. 
Thus, PSA levels should be cautiously interpreted when 
patients receive hormonal therapy.
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Introduction
The most reliable way to assess the clinical impact of an 
intervention is by its effect on a well-defined clinical end-
point. Hard clinical endpoints are the gold standard in 
efficacy evaluation of an intervention, but the need of long 
observation periods and large numbers of patients often 
limit their use in clinical trials. Therefore, biomarkers are 
increasingly introduced as substitutes in the assessment 
of clinical responses [1]. A biomarker that is intended to 
substitute for a clinical endpoint is called a surrogate end-
point. In the best case, biomarkers used as surrogates may 
improve the efficiency of clinical trials in which long-term 
disease interventions are evaluated, or enable outcome 
assessment in situations when meeting the substituted 
clinical endpoint would be regarded as ethically unaccep-
table. Nevertheless, it is important to be aware of several 
limitations in their applicability. According to the criteria 
for phase III clinical trials developed by Prentice [2], the 
surrogate should not only be a correlate of the true clinical 
outcome but fully capture the net effect of treatment on 
the clinical outcome. This is difficult to fulfil. For example, 
tissue specificity of prostate specific antigen (PSA) may 
not be as high as previously assumed, but PSA exists in 
extremely low concentrations in women [3, 4]. However, 
this is not clinically relevant in men. It was further shown 
that for time-to-event endpoints, the Prentice criteria are 
neither necessary nor sufficient to demonstrate that sur-
rogacy holds true [5].
It was therefore suggested that a biomarker as a sur-
rogate endpoint requires it to be “reasonably likely, based 
on epidemiologic, therapeutic, pathophysiologic or 
other evidence, to predict clinical benefit” [6], and a new 
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methodology known as the “meta-analytic validation” 
was developed to verify this [7].
PSA, a member of the family of kallikrein-related 
peptidases [8], is frequently used for the diagnosis and 
management of prostate cancer [9] and also as an outcome 
measure for relapsed disease [10] in prostate cancer trials. 
However, reliance on PSA kinetics alone may be mislead-
ing by several well-known mechanisms [11, 12]. Although 
it might be assumed that an agent causing a reduction in 
PSA would do so by reducing tumor burden, it is important 
to realize that drugs may produce PSA changes through 
mechanisms other than cell death. Theoretically, a drug-
induced reduction in the PSA synthesis or an enhanced 
PSA clearance rate would result in a decrease in PSA. Such 
effects may confound the value of PSA as predictive for a 
reduction in tumor size.
Functional androgen response can be found in the 
proximal promoter of the PSA gene [13]. A direct relation-
ship between androgen level and PSA synthesis on RNA 
[14] and protein-level has been described in vitro [15] and 
PSA was suggested to be a useful marker of testosterone 
activity in vivo [16, 17]. Further, androgen replacement 
therapy results in modest PSA elevations in healthy old 
men [18] as well as in men treated for hypogonadism or 
osteoporosis [19].
Based on these facts and in response to our incidental 
observations in a clinical trial evaluating a new leuprolide 
formulation [20], we hypothesized that treatment with a 
luteinizing hormone releasing hormone (LHRH) superag-
onist in healthy male volunteers would decrease plasma 
concentrations of PSA by suppression of testosterone to 
castration levels. The aim of the study was to assess the 
effect of a single intramuscular injection of a depot for-
mulation of a LHRH analog on testosterone and PSA levels 
over 56 days.
Materials and methods
Subjects and material
The protocol was approved by the Ethics Committee of the Medical 
University of Vienna. Written informed consent was obtained from all 
participants before inclusion. Healthy male subjects aged 18–45 years 
with normal body mass index (BMI) and vital parameters were eligi-
ble for enrolment. Exclusion criteria were regular or recent intake of 
medication including steroids in any form, abnormal baseline levels 
of testosterone or PSA and clinically relevant abnormal findings in 
medical history, physical examination or laboratory parameters.
On the main study day the 30 participants received a single intra-
muscular injection of a marketed depot formulation of a LHRH analog 
(Leuprolide 3.75 mg, Enantone®3,75, Takeda Chemical Industries, 
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Figure 1 Testosterone and prostate specific antigen (PSA) levels in 
healthy male volunteers (n = 30) after a single intramuscular injec-
tion of leuprolide.
(A) After an initial flare-up during the first 3 days, testosterone 
levels decreased and reached castration levels by day 21. After the 
nadir on day 28, testosterone levels increased again to baseline 
levels. (B) The initial increase in PSA levels occurred concomitantly 
with the increase in testosterone levels. The nadir was also reached 
on day 28. Thereafter PSA levels rose again to normal values. Data 
presented as means  ±  SEM, * p < 0.05, ** p < 0.01, *** p < 0.001.
Ltd., Japan). Such synthetic LHRH analogs have an increased dura-
tion of action and increased affinity for pituitary receptors. This 
induces down-regulation of the LHRH receptor and a post-receptor 
desensitization, resulting in reversible biochemical castration and is 
used as acetate salt to treat a wide range of sex hormone-related dis-
orders, including advanced prostatic cancer. Testosterone and PSA 
levels were determined at the points of time shown in Figure 1 from 
blood samples drawn in the morning (8 AM +1 h). All samples from 
each individual were run within one assay.
For testosterone measurements blood was collected in polypro-
pylene tubes, kept at room temperature for 30 min in order to sepa-
rate serum and then centrifuged at 1600 × g for 15 min. Serum was 
collected, divided in aliquots and stored at −70°C pending analysis. 
Samples packed in sufficient solid carbon dioxide, were shipped by 
an authorized courier to Bio-Inova France for analysis. Testosterone 
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levels were determined by radioimmunoassay (Behring Diagnostic; 
total precision: coefficient of variation  < 15%).
For the determination of total PSA blood was collected into 
tubes with separation gel and centrifuged at 3500 × g and 25°C for 
10 min. PSA was then determined by an electrochemiluminescence 
immunoassay “ECLIA” on the Roche Elecsys 2010 (Roche Diagnostics 
GmbH, Mannheim, Germany; intra-assay CV < 3%) [21].
Data analysis and visualization
For descriptive purposes, data are presented as means and standard 
deviations (SD), unless stated otherwise. The Friedman ANOVA and 
the Wilcoxon test were applied using Statistica 6.0 software (StatSoft 
Inc). Figures were created with Origin 7.0 (Origin Lab, Northampton, 
MA, USA).
Results
Baseline characteristics of the 30 healthy young males 
(mean age: 27 ± 5 years) are shown in Table 1. Figure 1 
shows the kinetics of testosterone and PSA levels in the 
men treated with a LHRH analog on day 0.
The expected “flare-up” effect in testosterone was 
reflected by an initial increase, which reached the 
maximum on day 3. Thereafter, testosterone concen-
trations dropped to nadir values reached on day 28 
(p < 0.0001). Castration (i.e., testosterone  < 0.5 ng/mL) was 
reached in 18 out of 30 males (60%). After day 35 the sub-
jects began to recover from castration and reached base-
line levels by day 56 (p = 0.46 compared to baseline).
PSA levels followed the changes in testosterone, first 
with a time lag of 3–7 days: after an initial slight rise with a 
maximum on day 7 they transiently decreased. The nadir 
was also reached on day 28, when PSA levels were reduced 
by 29% (95% CI 19%–39%, p < 0.0001 vs. baseline). There-
after, PSA levels rose again, normalizing by day 56.
Table 1 Baseline characteristics.
Baseline characteristics of the 30 healthy men
Age, years   27 ± 5
Body weight, kg   76.6 ± 9.2
Height, cm   178 ± 7
BMI, kg/m2   24.1 ± 2.5
Systolic BP, mm Hg   126 ± 9
Diastolic BP, mm Hg  70 ± 10
Heart rate, bpm   73 ± 9
Testosterone, μg/L   5.4 ± 1.3
PSA, μg/L   0.75 ± 0.29
Data presented as means ± SD. BMI, body mass index; BP, blood 
pressure; PSA, prostate- specific antigen.
Discussion
In patients with prostate cancer the decline in PSA 
after therapy with LHRH analogs is regarded as a sign 
of disease regression [22, 23]. This was the first trial to 
prospectively examine the influence of an LHRH analog 
on PSA levels. The data demonstrate a rapid response to 
LHRH in the sense of a pronounced decrease in PSA by 
approximately 30% in the absence of malignant disease. 
This decrease in PSA levels in healthy young male volun-
teers can certainly not be explained by tumor cell death 
or shrinkage of a prostatic hyperplasia, but might reflect 
an effect on cell metabolism by testosterone deprivation. 
However, when LHRH superagonists are used for the 
treatment of precocious puberty, they hold the further 
development of gonads and prolonged treatment of 
animals with LHRH superagonists may lead to reversible 
shrinkage of the testicles [24]. Although early trials in 
humans have indicated that LHRH analogs are not clini-
cally effective for the treatment of benign hypertrophic 
prostate [25], LHRH agonists or antagonists may revers-
ibly reduce prostate size in animals [26, 27]. However, 
the rapid flare-up in testosterone and consequently 
PSA cannot be due to shrinkage of the prostate and the 
rapid fall in PSA on day 14 after initiation of treatment 
is unlikely a consequence of prostate shrinkage which 
would be assumed to occur later.
The biomarker PSA seems to be directly affected by 
the intervention, i.e., treatment with the LHRH analog. In 
tumor patients LHRH analogs might similarly exert their 
effect on PSA not exclusively by influencing the disease, 
and an initial decrease in PSA levels might therefore not 
necessarily reflect treatment success. Indeed, there is 
evidence to suggest that androgen deprivation therapy 
(ADT) causes the initial decrease in PSA, not only because 
of tumor regression, but also because of suppression of 
androgen-dependent PSA gene transcription [28, 29]. The 
confirmed PSA suppression in the 30 healthy volunteers 
supports this hypothesis.
The phenomenon that declines in PSA levels might 
simply reflect the effect of the drug on the marker instead 
of an effect on cell growth or survival was also described 
for finasteride [30]. Finasteride is a 5α-reductase inhibi-
tor, which decreased PSA levels by 50% in elderly men 
(mean age: 64 ± 9 years) treated for benign prostatic hyper-
plasia for 12 months [31]. Finasteride use was associated 
with less but higher-grade prostate cancer in the Prostate 
Cancer Prevention Trial, which led to several specula-
tions regarding bias introduced by treatment induced 
PSA reduction [32]. It is essential to understand and doc-
ument a drug’s effect on PSA, since pure effects on PSA 
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production without any influence on tumor growth have 
been shown for potential cytotoxic drugs in phase II clini-
cal trials [33]. In both, prevention and treatment, changes 
in PSA are difficult to interpret, especially if they are influ-
enced by the intervention. It was therefore recommended 
that declines in PSA should be documented over time [34]. 
The studies on PSA velocity and other dynamic measures 
of PSA changes suggest that these might be more powerful 
than classical definitions of PSA changes using threshold 
values [35].
In the interpretation of PSA kinetics in clinical drug 
trials, the mechanism by which a drug exerts its effect 
on the tumor should be taken into account, as its influ-
ence on PSA may vary depending on whether a drug is 
directly cytotoxic or influences hormonal growth regula-
tion. Further, a drug-induced change in PSA might occur 
with or without a delay after treatment initiation. It was 
recommended that phase II or III clinical trials should 
be designed in a way that the PSA endpoint matches the 
anticipated effect of the tested drugs on PSA levels [35]. 
Therefore, PSA changes should routinely be documented 
even in phase I clinical trials to differentiate drug from 
treatment effects.
The question arises how our findings relate to tumor 
patients treated with LHRH analogs. In particular, base-
line PSA levels might not be reliable before day 28 after 
initiation of LHRH analog treatment. Repeated measure-
ments should be performed until the nadir is reached and 
an increase thereafter should be interpreted with caution. 
Clinicians using LHRH superagonists should not rely on 
PSA levels alone to judge clinical benefits, in agreement 
with the current recommendation not to use PSA end-
points in phase III trials [35].
One practical issue has to be considered: PSA with its 
extremely low detection limit of 0.01 ng/mL detects much 
earlier growing tumor cells than imaging. A PSA rise after 
prostate cancer therapy (operation, radiation, even LHRH 
therapy) from  < 0.01 to 0.2 cannot be detected by image 
diagnostics. In that seldom case that PSA levels remain 
low but stable after therapy there is a high probability that 
this PSA level is related to benign tissue PSA production. 
However, this conclusion can be drawn from the patient’s 
follow-up and his PSA levels.
PSA doubling time and velocity have mostly been 
studied for testing chemotherapeutic agents against 
hormone refractory prostate cancer and need further 
validation for their use in hormonally treated patients 
[35, 36].
It may be possible from a biochemical view that 
the PSA decrease after LHRH therapy may not be a 
treatment effect, but the question remains whether 
this could be clinically relevant. Mainly patients with 
advanced  prostate cancer receive LHRH, who have often 
undergone prostatectomy. It is clinically unimportant 
if there is a small rest of regular prostate tissue that is 
also affected by the LHRH. The PSA doubling time for 
patients with regular prostate tissue is lower than the 
doubling time in tumor patients that need LHRH. There-
fore this effect could be due to benign tissue only in 
those patients with remaining low PSA levels over a 
very long time (after treatment of their prostate cancer). 
However, it is unknown whether PSA in cancer cells is 
also under direct regulation of androgens as in normal 
prostate cells.
It is perhaps somewhat surprising that in only 18 
out of 30 men castration levels of testosterone were 
reached, although the LHRH superagonists should guar-
antee a castration level under regular clinical conditions. 
However this observation is consistent with the failure 
of another leuprolide product (Lucrin 3.75 mg) to lower 
testosterone levels below 0.5 ng/mL in three out of five 
healthy volunteers [20], and the failure of triptorelin to 
suppress testosterone levels in some treated patients 
[37]. This indicates that the lower leuprolide release from 
products of lower strength (3.75  mg instead of 7.5 mg) 
may be insufficient at least in younger subjects.
A potential limitation of this trial is that we have 
only measured total PSA (i.e., free and complexed PSA). 
Although, free PSA decreases more rapidly after prostatec-
tomy and LHRH antagonists [38] than complexed PSA, all 
forms of PSA show a similar kinetics, i.e., a slow and par-
allel decrease after initiation of hormonal treatment with 
LHRH analogs [39].
In summary, LHRH superagonists rapidly decrease 
PSA levels by testosterone deprivation. Thus, PSA levels 
should be interpreted with caution in patients receiving 
hormonal therapy.
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